Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer:: a single-center experience.

被引：0
|
作者：
Franco, S
Perez, A
Tan-Chiu, E
Frankel, C
Vogel, C
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [1] Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience
    Franco, S
    Perez, A
    Tan-Chiu, E
    Frankel, C
    Vogel, CL
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 (02) : 103 - 108
  • [2] Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience
    Sandra Franco
    Alejandra Perez
    Elizabeth Tan-chiu
    Cynthia Frankel
    Charles L. Vogel
    Breast Cancer Research and Treatment, 2004, 88 : 103 - 108
  • [3] Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
    Mlineritsch, Brigitte
    Psenak, Oskar
    Mayer, Peter
    Moik, Martin
    Namberger, Konrad
    Hauser-Kronberger, Cornelia
    Greil, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (01) : 105 - 112
  • [4] Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
    Brigitte Mlineritsch
    Oskar Psenak
    Peter Mayer
    Martin Moik
    Konrad Namberger
    Cornelia Hauser-Kronberger
    Richard Greil
    Breast Cancer Research and Treatment, 2007, 106
  • [5] Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer
    Martinez Marin, Virginia
    Munoz Martin, Andres J.
    Vinuela Beneitez, M. Carmen
    Garcia Alfonso, Pilar
    Alonso Munoz, Antonio
    Perez Manga, Gumersindo
    MEDICINA CLINICA, 2009, 133 (10): : 371 - 374
  • [6] Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Ahn, Yongchel
    Gong, Gyungyub
    Kim, Hak-Hee
    Kim, Hee-Jung
    Sun, Byung-Ho
    Alm, Sei-Hyun
    JOURNAL OF BREAST CANCER, 2011, 14 (02) : 135 - 139
  • [7] Case studies of fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer
    Abram, P
    Maass, N
    Rea, D
    Simon, SD
    Steger, GG
    CANCER TREATMENT REVIEWS, 2005, 31 : S17 - S25
  • [8] Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer
    Bundred, N
    CANCER INVESTIGATION, 2005, 23 (02) : 173 - 181
  • [9] Clinical benefit of fulvestrant in heavily pretreated patients with metastatic breast cancer
    Scandurra, Giuseppa
    Carillio, Guido
    Aiello, Rosa Anna
    Chiarenza, Maurizio
    Mazzola, Antonella
    Ali, Marco
    Barone, Gloria
    Greco, Filippo
    Caruso, Michele
    ANNALS OF ONCOLOGY, 2007, 18 : 44 - 44
  • [10] Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer
    Gevorgyan, Arpine
    Bregni, Giacomo
    Galli, Giulia
    Ganzinelli, Monica
    Martinetti, Antonia
    Lo Vullo, Salvatore
    Mariani, Luigi
    Festinese, Fabrizio
    Sottotetti, Elisa
    de Braud, Filippo
    Di Cosimo, Serena
    TUMORI, 2016, 102 (04) : E11 - E14
12345